Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch

The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) ra

Related Keywords

Texas ,United States ,New York ,Monique Kosse ,Nicole Sandford ,Lifesci Advisors ,Drug Administration ,Nasdaq ,Clinical Laboratory Fee Schedule ,Aspira Women Health Inc ,Women Health Inc ,Centers For Medicare Medicaid Services ,Laboratory Fee Schedule ,Medicaid Services ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Annual Report ,Medicare Administrative Carrier ,Aspira Labs ,Relations Contact ,Sci Advisors ,Ovarian Cancer ,Reimbursement Rate ,Inspira ,Womens Health ,Varian Malignancy ,